BiosanaPharma

If you aim to optimize your biomanufacturing facility’s OUTPUT while reducing CoGs, the adoption of Continuous Manufacturing (CM) is the ideal solution

BiosanaPharma has developed a highly flexible, comprehensive Continuous Manufacturing (CM) automation platform, suitable for all relevant GMP production scales (50L, 500L, and 2000L). Our 3C platform is unit operation-independent, and with integrated automatic sampling and on/at-line analytical, a continuous downstream process (DSP) can be fully implemented within 12 to 18 months.

Read our approach

We are on a mission to change biologics manufacturingARD TIJSTERMAN, CEO

The company has transitioned from technology development to licensing & implementation of CM technology at third-party facilities, including CDMOs, innovators, and biosimilar manufacturers.

Press release 11 September 2024

BiosanaPharma announces the launch of its Continuous Manufacturing licensing & implementation offering for the downstream processing of biologics

Press release 03 February 2022

BiosanaPharma and Alvotech close deal on omalizumab biosimilar

In the press 26 October 2021

Simplifying the bioprocessing journey

View all

Making biologics affordable and accessible for all patients

If you aim to optimize your biomanufacturing facility’s OUTPUT while reducing CoGs, the adoption of Continuous Manufacturing (CM) is the ideal solution

The company has transitioned from technology development to licensing & implementation of CM technology at third-party facilities, including CDMOs, innovators, and biosimilar manufacturers.

Press releases